Synaptic dysfunction in Huntington's disease: A new perspective

Cellular and Molecular Life Sciences

Volumn 62, Issue 17, 2005, Pages 1901-1912

  Smith, R ^a   Brundin, P ^a   Li, J Y ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Endocytosis; Exocytosis; Huntington's disease; Neurotransmission; Pathophysiology; Synaptic protein

Indexed keywords

HUNTINGTIN;

ASTROCYTE; ENDOCYTOSIS; EXOCYTOSIS; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; NEUROTRANSMISSION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SYNAPSE; SYNAPTIC TRANSMISSION; TRANSCRIPTION INITIATION; TRANSPORT VESICLE;

ANIMALS; BRAIN; EXOCYTOSIS; HUMANS; HUNTINGTON DISEASE; MODELS, ANIMAL; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; SYNAPSES; SYNAPTIC TRANSMISSION; TRANSCRIPTION, GENETIC;

EID: 24344461460     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-005-5084-5     Document Type: Review

References (135)

1. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983
2. Vonsattel J. P. and DiFiglia M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol. 57: 369-384
3. Harper P. S. (1996) Huntington's Disease, 2nd ed., W. B. Saunders, London
4. Bates G. P. and Davies S. W. (1997) Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions. Mol. Med. Today 3: 508-515
5. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. and Richardson E. P. Jr (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44: 559-577
6. Singhrao S. K., Thomas P., Wood J. D., MacMillan J. C., Neal J. W., Harper P. S. et al. (1998) Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's and Pick's diseases. Exp. Neurol. 150: 213-222
7. Hebb M. O., Denovan-Wright E. M. and Robertson H. A. (1999) Expression of the Huntington's disease gene is regulated in astrocytes in the arcuate nucleus of the hypothalamus of postpartum rats. FASEB J. 13: 1099-1106
8. Luthi-Carter R., Hanson S. A., Strand A. D., Bergstrom D. A., Chun W., Peters N. L. et al. (2002) Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11: 1911-1926
9. Orth M., Cooper J. M., Bates G. P. and Schapira A. H. (2003) Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J. Neurochem. 87: 1-6
10. Dragatsis I., Levine M. S. and Zeitlin S. (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26: 300-306
11. Andreassen O. A., Dedeoglu A., Stanojevic V., Hughes D. B., Browne S. E., Leech C. A. et al. (2002) Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol. Dis. 11: 410-424
12. Bjorkqvist M., Fex M., Renstrom E., Wierup N., Petersen A., Gil J. et al. (2005) The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient {beta}-cell mass and exocytosis. Hum. Mol. Genet., in press
13. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C. et al. (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14: 1075-1081
14. Velier J., Kim M., Schwarz C., Kim T. W., Sapp E., Chase K. et al. (1998) Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways. Exp. Neurol. 152: 34-40
15. Gutekunst C. A., Li S. H., Yi H., Ferrante R. J., Li X. J. and Hersch S. M. (1998) The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. J. Neurosci. 18: 7674-7686
16. Hilditch-Maguire P., Trettel F., Passani L. A., Auerbach A., Persichetti F. and MacDonald M. E. (2000) Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 9: 2789-2797
17. Nasir J., Floresco S. B., O'Kusky J. R., Diewert V. M., Richman J. M., Zeisler J. et al. (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81: 811-823
18. Rigamonti D., Bauer J. H., De-Fraja C., Conti L., Sipione S., Sciorati C. et al. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20: 3705-3713
19. Goffredo D., Rigamonti D., Tartari M., De Micheli A., Verderio C., Matteoli M. et al. (2002) Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J. Biol. Chem. 277: 39594-39598
20. Li S. H. and Li X. J. (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20: 146-154
21. Engelender S., Sharp A. H., Colomer V., Tokito M. K., Lanahan A., Worley P. et al. (1997) Huntingtin-associated protein 1 (HAP1) interacts with the p150(Glued) subunit of dynactin. Hum. Mol. Genet. 6: 2205-2212
22. Glued. J. Neurosci. 18: 1261-1269
23. Trushina E., Dyer R. B., Badger J. D. 2nd, Ure D., Eide L., Tran D. D. et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 24: 8195-8209
24. Gauthier L. R., Charrin B. C., Borrell-Pages M., Dompierre J. P., Rangone H., Cordelieres F. P. et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118: 127-138
25. Gutekunst C. A., Levey A. I., Heilman C. J., Whaley W. L., Yi H., Nash N. R. et al. (1995) Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. USA 92: 8710-8714
26. Hoffner G., Kahlem P. and Djian P. (2002) Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. J. Cell Sci. 115: 941-948
27. Szebenyi G., Morfini G. A., Babcock A., Gould M., Selkoe K., Stenoien D. L. et al. (2003) Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40: 41-52
28. Gunawardena S., Her L. S., Brusch R. G., Laymon R. A., Niesman I. R., Gordesky-Gold B. et al. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40: 25-40
29. Ciechanover A. and Brundin P. (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40: 427-446
30. Fink A. L. (1999) Chaperone-mediated protein folding. Physiol. Rev. 79: 425-449
31. Hartl F. U. and Hayer-Hartl M. (2002) Molecular chaperones in the cytosol: from nascent chain to folded protein. Science 295: 1852-1858
32. Lunkes A., Lindenberg K. S., Ben-Haiem L., Weber C., Devys D., Landwehrmeyer G. B. et al. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell. 10: 259-269
33. Li H., Wyman T., Yu Z. X., Li S. H. and Li X. J. (2003) Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum. Mol. Genet. 12: 2021-2030
34. Qin Z. H., Wang Y., Sapp E., Cuiffo B., Wanker E., Hayden M. R. et al. (2004) Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J. Neurosci. 24: 269-281
35. Waelter S., Boeddrich A., Lurz R., Scherzinger E., Lueder G., Lehrach H. et al. (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell 12: 1393-1407
36. Doi H., Mitsui K., Kurosawa M., Machida Y., Kuroiwa Y. and Nukina N. (2004) Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett. 571: 171-176
37. Donaldson K. M., Li W., Ching K. A., Batalov S., Tsai C. C. and Joazeiro C. A. (2003) Ubiquitin-inediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc. Natl. Acad. Sci. USA 100: 8892-8897
38. Sakahira H., Breuer P., Hayer-Hartl M. K. and Hartl F. U. (2002) Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Proc. Natl. Acad. Sci. USA 99 (suppl. 4): 16412-16418
39. Steffan J. S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y. Z., Gohler H. et al. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 97: 6763-6768
40. Nucifora F. C. Jr, Sasaki M., Peters M. F., Huang H., Cooper J. K., Yamada M. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291: 2423-2428.
41. Sugars K. L., Brown R., Cook L. J., Swartz J. and Rubinsztein D. C. (2004) Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J. Biol. Chem. 279: 4988-4999
42. Wyttenbach A., Swartz J., Kita H., Thykjaer T., Carmichael J., Bradley J. et al. (2001) Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 10: 1829-1845
43. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L. et al. (2003) Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35: 76-83
44. Li S. H., Cheng A. L., Zhou H., Lam S., Rao M., Li H. et al. (2002) Interaction of Huntington disease protein with transcriptional activator sp1. Mol. Cell. Biol. 22: 1277-1287
45. Dunah A. W., Jeong H., Griffin A., Kim Y. M., Standaert D. G., Hersch S. M. et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296: 2238-2243
46. Sugars K. L. and Rubinsztein D. C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet. 19: 233-238
47. Landles C. and Bates G. P. (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO Rep. 5: 958-963
48. Obrietan K. and Hoyt K. R. (2004) CRE-mediated transcription is increased in Huntington's disease transgenic mice. J. Neurosci. 24: 791-796
49. Yu Z. X., Li S. H., Nguyen H. P. and Li X. J. (2002) Huntingtin inclusions do not deplete polyglutamine-containing transcription factors in HD mice. Hum. Mol. Genet. 11: 905-914
50. Luthi-Carter R., Strand A. D., Hanson S. A., Kooperberg C., Schilling G., La Spada A. R. et al. (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11: 1927-1937
51. Chan E. Y., Luthi-Carter R., Strand A., Solano S. M., Hanson S. A., DeJohn M. M. et al. (2002) Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum. Mol. Genet. 11: 1939-1951
52. Sipione S., Rigamonti D., Valenza M., Zuccato C., Conti L., Pritchard J. et al. (2002) Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum. Mol. Genet. 11: 1953-1965
53. Schoenherr C. J., Paquette A. J. and Anderson D. J. (1996) Identification of potential target genes for the neuron restrictive silencer factor. Proc. Natl. Acad. Sci. USA 93: 9881-9886
54. Li J. Y., Plomann M. and Brundin P. (2003) Huntington's disease: a synaptopathy? Trends Mol. Med. 9: 414-420
55. Lin R. C. and Scheller R. H. (2000) Mechanisms of synaptic vesicle exocytosis. Annu. Rev. Cell Dev. Biol. 16: 19-49
56. Fon E. A. and Edwards R. H. (2001) Molecular mechanisms of neurotransmitter release. Muscle Nerve 24: 581-601
57. Ziv N. E. and Garner C. C. (2004) Cellular and molecular mechanisms of presynaptic assembly. Nat. Rev. Neurosci. 5: 385-399
58. Wyttenbach A., Carmichael J., Swartz J., Furlong R. A., Narain Y., Rankin J. et al. (2000) Effects of heat shock, heat shock protein 40 (HDJ-2) and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 97: 2898-2903
59. Lievens J. C., Woodman B., Mahal A. and Bates G. P. (2002) Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol. Cell. Neurosci. 20: 638-648
60. Rizo J. and Sudhof T. C. (2002) Snares and Munc18 in synaptic vesicle fusion. Nat. Rev. Neurosci. 3: 64-653
61. Morton A. J. and Edwardson J. M. (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J. Neurochem. 76: 166-172
62. Morton A. J., Faull R. L. and Edwardson J. M. (2001) Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull. 56: 111-117
63. Edwardson J. M., Wang C. T., Gong B., Wyttenbach A., Bai J., Jackson M. B. et al. (2003) Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J. Biol. Chem. 278: 30849-30853
64. Glynn D., Bortnick R. A. and Morton A. J. (2003) Complexin II is essential for normal neurological function in mice. Hum. Mol. Genet. 12: 2431-2448
65. Smith R., Petersen A., Bates G., Brundin P. and Li J. Y. (2005) Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. Neurobiol. Dis., in press
66. Chung S. H., Takai Y. and Holz R. W. (1995) Evidence that the Rab3a-binding protein, rabphilin3a, enhances regulated secretion. Studies in adrenal chromaffin cells. J. Biol. Chem. 270: 16714-16718
67. Greengard P., Valtorta F., Czernik A. J. and Benfenati F. (1993) Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 259: 780-785
68. Baines A. J. and Bennett V. (1986) Synapsin I is a microtubule-bundling protein. Nature 319: 145-147
69. Hansson O., Guatteo E., Mercuri N. B., Bernardi G., Li X. J., Castilho R. F. et al. (2001) Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur. J. Neurosci. 14: 1492-1504
70. Miller L. C., Swayne L. A., Chen L., Feng Z. P., Wacker J. L., Muchowski P. J. et al. (2003) Cysteine string protein (CSP) inhibition of N-type calcium channels is blocked by mutant huntingtin. J. Biol. Chem. 278: 53072-53081
71. Tang T. S., Tu H., Chan E. Y., Maximov A., Wang Z., Wellington C. L. et al. (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39: 227-239
72. Cha J. H., Kosinski C. M., Kerner J. A., Alsdorf S. A., Mangiarini L., Davies S. W. et al. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. USA 95: 6480-6485
73. Singaraja R. R., Hadano S., Metzler M., Givan S., Wellington C. L., Warby S. et al. (2002) HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum. Mol. Genet. 11: 2815-2828
74. Modregger J., DiProspero N. A., Charles V., Tagle D. A. and Plomann M. (2002) PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum. Mol. Genet. 11: 2547-2558
75. Kalchman M. A., Koide H. B., McCutcheon K., Graham R. K., Nichol K., Nishiyama K. et al. (1997) HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat. Genet.16: 44-53
76. Sittler A., Walter S., Wedemeyer N., Hasenbank R., Scherzinger E., Eickhoff H. et al. (1998) SH3GL3 associates with the huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol. Cell. 2: 427-436
77. Wanker E. E., Rovira C., Scherzinger E., Hasenbank R., Walter S., Tait D. et al. (1997) HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6: 487-495
78. Li X. J., Li S. H., Sharp A. H., Nucifora F. C. Jr, Schilling G., Lanahan A. et al. (1995) A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378: 398-402
79. Gill S. R., Schroer T. A., Szilak I., Steuer E. R., Sheetz M. P. and Cleveland D. W. (1991) Dynactin, a conserved, ubiquitously expressed component of an activator of vesicle motility mediated by cytoplasmic dynein. J. Cell Biol. 115: 1639-1650
80. Li Y., Chin L. S., Levey A. I. and Li L. (2002) Huntingtin-associated protein 1 interacts with hepatocyte growth factor-regulated tyrosine kinase substrate and functions in endosomal trafficking. J. Biol. Chem. 277: 28212-28221
81. Engqvist-Goldstein A. E., Kessels M. M., Chopra V. S., Hayden M. R. and Drubin D. G. (1999) An actin-binding protein of the Sla2/huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J. Cell Biol. 147: 1503-1518
82. Legendre-Guillemin V., Metzler M., Charbonneau M., Gan L., Chopra V., Philie J. et al. (2002) HIP1 and HIP12 display differential binding to F-actin, AP2 and clathrin. Identification of a novel interaction with clathrin light chain. J. Biol. Chem. 277: 19897-19904
83. Modregger J., Schmidt A. A., Ritter B., Huttner W. B. and Plomann M. (2003) Characterization of endophilin B1b, a brain-specific membrane-associated lysophosphatidic acid acyl transferase with properties distinct from endophilin A1. J. Biol. Chem. 278: 4160-4167
84. Nicniocaill B., Haraldsson B., Hansson O., O'Connor W. T. and Brundin P. (2001) Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. Eur. J. Neurosci. 13: 206-210
85. Behrens P. F., Franz P., Woodman B., Lindenberg K. S. and Landwehrmeyer G. B. (2002) Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125: 1908-1922
86. Testa C. M., Friberg I. K., Weiss S. W. and Standaert D. G. (1998) Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia. J. Comp. Neurol. 390: 5-19
87. Cartmell J. and Schoepp D. D. (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem. 75: 889-907
88. Levine M. S., Klapstein G. J., Koppel A., Gruen E., Cepeda C., Vargas M. E. et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res. 58: 515-532
89. Hodgson J. G., Agopyan N., Gutekunst C. A., Leavitt B. R., LePiane F., Singaraja R. et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity and selective striatal neurodegeneration. Neuron 23: 181-192
90. Sun Y., Savanenin A., Reddy P. H. and Liu Y. F. (2001) Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276: 24713-24718
91. Luthi-Carter R., Apostol B. L., Dunah A. W., DeJohn M. M., Farrell L. A., Bates G. P. et al. (2003) Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins and phosphorylation. Neurobiol. Dis. 14: 624-636
92. Arzberger T., Krampfl K., Leimgruber S. and Weindl A. (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease - an in situ hybridization study. J. Neuropathol. Exp. Neurol. 56: 440-454
93. Wyszynski M., Lin J., Rao A., Nigh E., Beggs A. H., Craig A. M. et al. (1997) Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Nature 385: 439-442
94. Kato M., Sasaki T., Ohya T., Nakanishi H., Nishioka H., Imamura M. et al. (1996) Physical and functional interaction of rabphilin-3A with alpha-actinin. J. Biol. Chem. 271: 31775-31778
95. Li L., Murphy T. H., Hayden M. R. and Raymond L. A. (2004) Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor mediated synaptic currents in a mouse model of Huntington disease. J. Neurophysiol. 92: 2738-2746
96. Jarabek B. R., Yasuda R. P. and Wolfe B. B. (2004) Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 127: 505-516
97. Hansson O., Petersén Å., Leist M., Nicotera P., Castilho R. F. and Brundin P. (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc. Natl. Acad. Sci. USA 96: 8727-8732
98. Hansson O., Castilho R. F., Korhonen L., Lindholm D., Bates G. P. and Brundin P. (2001) Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J. Neurochem. 78: 694-703
99. MacGibbon G. A., Hamilton L. C., Crocker S. F., Costain W. J., Murphy K. M., Robertson H. A. et al. (2002) Immediate-early gene response to methamphetamine, haloperidol and quinolinic acid is not impaired in Huntington's disease transgenic mice. J. Neurosci. Res. 67: 372-378
100. Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P. et al. (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33: 849-860
101. Petersen A., Chase K., Puschban Z., DiFiglia M., Brundin P. and Aronin N. (2002) Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease. Exp. Neurol. 175: 297-300
102. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506
103. Petersen A., Puschban Z., Lotharius J., NicNiocaill B., Wiekop P., O'Connor W. T. et al. (2002) Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol. Dis. 11: 134-146
104. van Dellen A., Welch J., Dixon R. M., Cordery P., York D., Styles P. et al. (2000) N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport 11: 3751-3757
105. Bibb J. A., Yan Z., Svenningsson P., Snyder G. L., Pieribone V. A., Horiuchi A. et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. USA 97: 6809-6814
106. Saudou F., Finkbeiner S., Devys D. and Greenberg M. E. (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95: 55-66
107. Kremer H. P., Roos R. A., Dingjan G., Marani E. and Bots G. T. (1990) Atrophy of the hypothalamic lateral tuberal nucleus in Huntington's disease. J. Neuropathol. Exp. Neurol. 49: 371-382
108. Kremer H. P., Roos R. A., Dingjan G. M., Bots G. T., Bruyn G. W. and Hofman M. A. (1991) The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease. Neurosci. Lett. 132: 101-104
109. Caramins M., Halliday G., McCusker E. and Trent R. J. (2003) Genetically confirmed clinical Huntington's disease with no observable cell loss. J. Neurol. Neurosurg. Psychiatry 74: 968-970
110. Mizuno H., Shibayama H., Tanaka F., Doyu M., Sobue G., Iwata H. et al. (2000) An autopsy case with clinically and molecular genetically diagnosed Huntington's disease with only minimal non-specific neuropathological findings. Clin. Neuropathol. 19: 94-103
111. DiFiglia M., Sapp E., Chase K. O., Davies S. W., Bates G. P., Vonsattel J. P. et al. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277: 1990-1993
112. Graveland G. A., Williams R. S. and DiFiglia M. (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227: 770-773
113. Guidetti P., Charles V., Chen E. Y., Reddy P. H., Kordower J. H., Whetsell W. O. Jr. et al. (2001) Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp. Neurol. 169: 340-350
114. Menalled L. B. and Chesselet M. F. (2002) Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23: 32-39
115. Schilling G., Becher M. W., Sharp A. H., Jinnah H. A., Duan K., Kotzuk J. A. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8: 397-407
116. Slow E. J., Van Raamsdonk J., Rogers D., Coleman S. H., Graham R. K., Deng Y. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 12: 1555-1567
117. Reddy P. H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W. O. Jr et al. (1998) Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20: 198-202
118. Petersen A., Gil J., Maat-Schieman M. L., Bjorkqvist M., Tanila H., Araujo I. M. et al. (2005) Orexin loss in Huntington's disease. Hum. Mol. Genet. 14: 39-47
119. Luthi-Carter R., Strand A., Peters N. L., Solano S. M., Hollingsworth Z. R., Menon A. S. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9: 1259-1271
120. Bogdanov M. B., Andreassen O. A., Dedeoglu A., Ferrante R. J. and Beal M. F. (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79: 1246-1249
121. Santamaria A., Perez-Severiano F., Rodriguez-Martinez E., Maldonado P. D., Pedraza-Chaverri J., Rios C. et al. (2001) Comparative analysis of superoxide dismutase activity between acute pharmacological models and a transgenic mouse model of Huntington's disease. Neurochem. Res. 26: 419-424
122. Tabrizi S. J., Workman J., Hart P. E., Mangiarini L., Mahal A., Bates G. et al. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47: 80-86
123. Perez-Severiano F., Escalante B., Vergara P., Rios C. and Segovia J. (2002) Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res. 951: 36-42
124. Deckel A. W., Gordinier A., Nuttal D., Tang V., Kuwada C., Freitas R. et al. (2001) Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of L-NAME on symptom progression. Brain Res. 919: 70-81
125. Deckel A. W., Tang V., Nuttal D., Gary K. and Elder R. (2002) Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice. Brain Res. 939: 76-86
126. Petersen A., Larsen K. E., Behr G. G., Romero N., Przedborski S., Brundin P. et al. (2001) Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum. Mol. Genet. 10: 1243-1254
127. Cepeda C., Hurst R. S., Calvert C. R., Hernandez-Echeagaray E., Nguyen O. K., Jocoy E. et al. (2003) Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J. Neurosci. 23: 961-969
128. Lievens J. C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L. et al. (2001) Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 8: 807-821
129. Hickey M. A., Reynolds G. P. and Morton A. J. (2002) The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J. Neurochem. 81: 46-59
130. Reynolds G. P., Dalton C. F., Tillery C. L., Mangiarini L., Davies S. W. and Bates G. P. (1999) Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. J. Neurochem. 72: 1773-1776
131. Ariano M. A., Aronin N., Difiglia M., Tagle D. A., Sibley D. R., Leavitt B. R. et al. (2002) Striatal neurochemical changes in transgenic models of Huntington's disease. J. Neurosci. Res. 68: 716-729
132. Yohrling I. G., Jiang G. C., DeJohn M. M., Robertson D. J., Vrana K. E. and Cha J. H. (2002) Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease. J. Neurochem. 82: 1416-1423
133. Cha J. H., Frey A. S., Alsdorf S. A., Kerner J. A., Kosinski C. M., Mangiarini L. et al. (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354: 981-989
134. van Dellen A., Blakemore C., Deacon R., York D. and Hannan A. J. (2000) Delaying the onset of Huntington's in mice. Nature 404: 721-722
135. Zucker B., Luthi-Carter R., Kama J. A., Dunah A. W., Stern E. A., Fox J. H. et al. (2005) Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum. Mol. Genet. 14: 179-189